ALKS241220C34000
- 0.00
- 0.000.00%
Alkermes Newsroom
Alkermes to Participate in Upcoming Investor Conferences
Investing in Alkermes (NASDAQ:ALKS) Five Years Ago Would Have Delivered You a 39% Gain
Mizuho Securities Maintains Alkermes(ALKS.US) With Buy Rating
Alkermes Buy Recommendation: Strong Drug Pipeline and Strategic Growth Initiatives Highlighted
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Alkermes To Participate In Jefferies London Healthcare Conference At 8:00 AM ET
Alkermes To Present At Stifel Healthcare Conference; Webcast At 8:35 AM ET
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
US Manufacturing Index Rises To 43, Highest Since 2020
BofA Securities Maintains Alkermes(ALKS.US) With Hold Rating
Bank of America Securities Keeps Their Hold Rating on Alkermes (ALKS)
Mizuho Securities Maintains Alkermes(ALKS.US) With Buy Rating, Announces Target Price $40
Alkermes Is Maintained at Outperform by Mizuho
Express News | Alkermes PLC : Mizuho Raises Target Price to $40 From $35
Alkermes Insider Sold Shares Worth $1,774,576, According to a Recent SEC Filing
TD Cowen Maintains Alkermes(ALKS.US) With Buy Rating, Maintains Target Price $35
Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
Alkermes Raised to Buy by Stifel on Increased Confidence for ALKS2680
Stifel Maintains Alkermes(ALKS.US) With Buy Rating, Maintains Target Price $36